{
    "paper_id": "3223744f9644fe3ceffadd412ae0e73ca39fec6c",
    "metadata": {
        "title": "Supporting Information COVID-19: Living Through Yet Another Pandemic",
        "authors": [
            {
                "first": "Essam",
                "middle": [],
                "last": "Eldin",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "A",
                "middle": [],
                "last": "Osman",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Cairo University",
                    "location": {
                        "postCode": "11562",
                        "settlement": "Cairo",
                        "country": "Egypt"
                    }
                },
                "email": ""
            },
            {
                "first": "Peter",
                "middle": [
                    "L"
                ],
                "last": "Toogood",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Michigan",
                    "location": {
                        "postCode": "48109",
                        "settlement": "Ann Arbor",
                        "region": "MI"
                    }
                },
                "email": ""
            },
            {
                "first": "Nouri",
                "middle": [],
                "last": "Neamati",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Non-structural protein 9 (nsp9).",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "May participate in viral replication by acting as a ssRNA-binding protein.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "113"
        },
        {
            "text": "Non-structural protein 10 (nsp10).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6W4B 6W9Q"
        },
        {
            "text": "Formerly known as growth-factor-like protein (GFL). Plays a pivotal role in viral transcription by stimulating both 3'-5' exoribonuclease (nsp14) and 2'-Omethyltransferase (nsp16) activities. Therefore, plays an essential role in viral mRNAs cap methylation. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "139"
        },
        {
            "text": "Multi-functional protein with a zinc-binding domain in N-terminus displaying RNA and DNA duplex-unwinding activities with 5' to 3' polarity. Activity of helicase is dependent on magnesium.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "601"
        },
        {
            "text": "None 31131400 28651017",
            "cite_spans": [],
            "ref_spans": [],
            "section": "601"
        },
        {
            "text": "Guanine-N7 methyltransferase (ExoN). (nsp14).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "601"
        },
        {
            "text": "Enzyme possessing two different activities: an exoribonuclease activity acting on both ssRNA and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase activity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "527"
        },
        {
            "text": "Uridylate-specific endoribonuclease (NendoU) (nsp15).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "None 26159422 29279395"
        },
        {
            "text": "Mn 2+dependent, uridylate-specific enzyme, which leaves 2'-3'-cyclic phosphates 5' to the cleaved bond.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "346"
        },
        {
            "text": "16882730 17409150",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6W01 6VWW"
        },
        {
            "text": "Methyltransferase that mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16. Therefore, plays an essential role in viral mRNAs cap methylation which is essential to evade immune system.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "298"
        },
        {
            "text": "21637813",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6W4H 6W75"
        },
        {
            "text": "1273 Spike protein S1 (residue 14- Phase 4 Data were collected from https://clinicaltrials.gov/ when searched for: covid-19, SARS-CoV-2, 2019-nCoV, and 2019 novel coronavirus (accessed on April 18, 2020). The Table represents the unique therapeutic entities that may be used as single agents or in combination. The recorded phases are the highest phase reached by each entity",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Surface glycoprotein (S)."
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Pandemics: risks, impacts, and mitigation",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Madhav",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Oppenheim",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gallivan",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Mulembakani",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Rubin",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Wolfe",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Disease Control Priorities: Improving Health and Reducing Poverty",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Structures of select approved or investigational drugs tested for drug repurposing against SARS-Structures of the novel inhibitors obtained from the PDB for SARS-CoV-2 M pro and rupintrivir",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Ruxolitinib (inhibitor of Janus kinase (JAK)) Phase 1/2 Baricitinib (inhibitor of Janus kinase (JAK)) Phase 3 CD24Fc (CD24 extracellular domain-IgG1 Fc domain recombinant fusion protein) Phase 3 CM4620 (inhibitor of CRAC channels) Phase 2 Monoclonal antibody Bevacizumab (vascular endothelial growth factor A (VEGF-A) antibody) Phase 2/3 Tocilizumab (interleukin-6 receptor (IL-6R) antibody) Phase 4 Sarilumab (interleukin-6 receptor (IL-6R) antibody) Phase 2/3 Clazakizumab (humanized rabbit monoclonal antibody against IL-6) Phase 2/3 Siltuximab (chimeric monoclonal antibody for IL-6) Phase 3 Anakinra (recombinant human interleukin-1 receptor antagonist (IL-1Ra) Phase 4 Meplazumab (anti-CD147) Phase 1/2 IFX-1 (complement factor C5a) Phase 2/3 Emapalumab (immunoglobulin G1 monoclonal antibody for interferon-\u03b3 (IFN-\u03b3Nitazoxanide (antiprotozoal) Phase 4 Defibrotide (mixture of single-stranded oligonucleotides for veno-occlusive diseases) Phase 2 Verapamil (calcium channel blocker) Phase 2/3 Amiodarone (class III antiarrhythmic) Phase 2/3 Valsartan (angiotensin receptor blocker, anti-hypertensive) Phase 4 Losartan (angiotensin receptor blocker, anti-hypertensive) collected from https://clinicaltrials.gov/ when searched for: covid-19, SARS-CoV-2, 2019-nCoV, and 2019 novel coronavirus (accessed on April 17, 2020). TheTable representsthe unique therapeutic entities that may be used as single agents or in combination. The recorded phases are the highest phase reached by each entity",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Viral outbreaks since year 2000 Different targets expressed in SARS-CoV-2 proteome (genome accession code: NC_045512.2 or MN908947.3), their length, potential functions extracted from Uniprot and crystal structures in Protein Data Bank (PDB) Unique therapeutic interventions in recruiting clinical studies Unique therapeutic interventions in non-recruiting clinical studies",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Viral outbreaks since year 2000 1",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Different targets expressed in SARS-CoV-2 proteome (genome accession code: NC_045512.2 or MN908947.3), their length, potential functions extracted from Uniprot and crystal structures in Protein Data Bank (PDB)",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Spike protein S2' (residue 816-1273): acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis.",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "Unique therapeutic interventions in recruiting clinical studies",
            "latex": null,
            "type": "table"
        },
        "TABREF6": {
            "text": "Unique therapeutic interventions in non-recruiting clinical studies PUL-042 (toll-like receptor2/6/9 (TLR) ligands) Phase 2 Thymosin alpha 1 (peptide hormone) Phase 2 Monoclonal antibody Sarilumab (interleukin-6 receptor (IL-6R)) Phase 2/3 Tocilizumab (interleukin-6 receptor (IL-6R)) Phase 3 Anakinra (recombinant human interleukin-1 receptor antagonist (IL-1Ra) Phase 4 BMS-986253 (IL-8 antibody)Phase 2 Mavrilimumab (granulocyte-macrophage colony-stimulating factor antibody) Phase 2 Lenzilumab (colony stimulating factor 2 /granulocyte-macrophage colony stimulating factor antibody)",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": " Figure S1 . Structures of select approved or investigational drugs tested for drug repurposing against SARS-CoV2 Figure S2 . Structures of the novel inhibitors obtained from the PDB for SARS-CoV-2 M pro and rupintrivir",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 1,
                    "end": 10,
                    "text": "Figure S1",
                    "ref_id": null
                },
                {
                    "start": 114,
                    "end": 123,
                    "text": "Figure S2",
                    "ref_id": null
                }
            ],
            "section": "annex"
        }
    ]
}